Company news

Crinetics Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

June 27, 2021

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

June 15, 2021

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 5, 2021

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

April 11, 2021

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

March 29, 2021

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

March 23, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

March 21, 2021

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

March 11, 2021

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

February 3, 2021

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

February 2, 2021

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Crinetics Pharmaceuticals to Participate in December Investor Conferences

November 22, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

November 15, 2020

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly

November 12, 2020

Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 5, 2020

Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint

October 25, 2020

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

September 20, 2020

Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

September 3, 2020

Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors

September 2, 2020

Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 6, 2020

Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly

July 7, 2020

Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine

June 10, 2020

Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources

May 26, 2020

Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 7, 2020

Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update

April 5, 2020

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 8, 2020

Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 11, 2019

← Newer news releases

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.